We use cookies for a better user experience. Read our Privacy Policy

I Agree

Neurotrophic Keratitis Market

Neurotrophic Keratitis Market (Treatment Type: Drugs (Artificial Tears, Recombinant Human Nerve Growth Factors Eye Drops, Antibiotics, Bandage Contact Lens, and Others) and Surgical Intervention (Tarsorrhaphy, Amniotic Membrane Transplantation, and Others); and Application: Stage I, Stage II, and Stage III) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

R&D Activities to Accelerate Discovery of New Treatments and Drugs

Within the healthcare sector, research and development activities play an imperative role in the discovery of new treatments. The prevalence of neurotrophic keratitis is relatively low due to which, there were no approved drugs in the market to treat the rare eye disease. However, over the past decade, there were significant investments for the development and discovery of drugs that could potentially treat the rare eye disease. Progress in biotechnology has enabled the development of new biological treatments that address neurotrophic keratitis. Moreover, research and development activities have received an added push over the past few years, due to a steady rise in the number of neurotrophic keratitis.

While developed regions such as North America and Europe are likely to present lucrative opportunities for players involved in the current neurotrophic keratitis market landscape due to favorable reimbursement policies and concrete healthcare infrastructure in these regions. However, the neurotrophic keratitis market in developing regions such as Asia Pacific is expected to witness significant developments during the forecast period, due to growing government investments in healthcare and R&D. Thus, the global neurotrophic keratitis market is projected to attain a market value of US$ 324 Mn by the end of 2027.

neurotrophic keratitis market infographic

To know the scope of our report Get a Sample on Neurotrophic Keratitis Market

Drug Developers Aim for FDA Approval for Newly Developed Drugs

For drug developers, apart from research and development, receiving the approval from the FDA is one of the most critical stages of the drug development process. Within the neurotrophic keratitis market, the lack of approved drugs for neurotrophic keratitis provided a window of opportunity for drug developers. Innovations and progress in the development of new drugs will continue to influence the growth of the neurotrophic keratitis market during the assessment period. In 2018, the U.S. Food and Drug Administration waved the green flag and approved Oxervate, a drug developed by an Italian pharmaceutical company, Dompé. Moreover, Oxervate, stands to remain the first-ever drug to receive the approval from the FDA for the treatment of neurotrophic keratitis. Despite having a significantly lower prevalence rate, neurotrophic keratitis can have a devastating impact on individuals suffering from this disease.

Receiving approval from the FDA is tipped to be one of the most groundbreaking developments in the current neurotrophic keratitis market, and likely to pave the way for new drugs and treatments during the forecast period. While the FDA approval marks the beginning of new drug development activities in the neurotrophic keratitis market, drug developers are also expected to invest resources to curb the adverse reactions of these drugs.

Get a glimpse of the in-depth analysis through our Report Brochure

Stakeholders Explore Different Treatments to Cure Neurotrophic Keratitis

In the past few years, research and development activities have gained considerable amount of traction in the neurotrophic keratitis market. Clinical trials on different animals have revealed that corneal denervation minimizes corneo limbal stem cell function and number– a factor that could cause the development of epithelial ulcers experienced by patients suffering from neurotrophic keratitis. At present, some of the most notable treatments offered to treat neurotrophic keratitis include autologous serum eye drops, tarsorrhaphy, gold weight placement, punctual closure, and bandage contact lenses. The recombinant human nerve growth factors eye drops sub-segment segment of the drugs segment is projected to gain significant popularity in the second half of the forecast period and emerge as one of the most vital treatment types due to the growing evidence supporting the efficacy of the treatment. Some of the key parameters that are used to assess the efficacy of treatment include corneal healing, corneal sensitivity, and duration of corneal healing, among others.

neurotrophic keratitis market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

The global neurotrophic keratitis market is expected to grow at a staggering CAGR of ~17% during the forecast period. The impressive market growth will be driven by a range of factors, including rise in the number of neurotrophic keratitis cases across the world and surge in co-morbidities and risk factors. Moreover, research and development activities for the development of new treatment and drugs will continue to define the course of the market for neurotrophic keratitis during the forecast period. Drug developers and key participants in the current market landscape will eagerly anticipate obtaining the FDA approval for their drugs and treatment. While North America and Europe are expected to lead in terms of market share and value, Asia Pacific region will continue to present lucrative opportunities for market players.  

Neurotrophic Keratitis Market: Overview

  • According to Transparency Market Research’s latest report on the global neurotrophic keratitis market for the historical period 2017–2018 and forecast period 2019–2027, rise in reported cases of keratitis, surge in number of surgical procedures such as corneal surgery and neurosurgery; overuse of topical medications and contact lenses, and introduction of new therapies are projected to drive the global neurotrophic keratitis market
  • According to the report, the global neurotrophic keratitis market was valued at US$ 91.6 Mn in 2018 and is anticipated to expand at a CAGR of ~17% from 2019 to 2027

Increase in Reported Cases of Keratitis: A Key Driver

  • According to New York Eye and Ear Infirmary, keratitis resulting from an infection is among the leading causes of preventable blindness across the world. Incidence of the disease is quite high in developing countries, estimated at 500,000 per year. The number of cases in the U.S. ranges from 25,000 to 30,000 per year.
  • According to the National Institute for Health Research, neurotrophic keratitis develops in on average 6% of herpetic keratitis patients (prevalence of 149 per 100,000 population) and in 13% of herpes zoster keratitis patients (prevalence of 26 per 100,000 population). Additionally, 2.8% patients who underwent surgical procedures for trigeminal neuralgia (1.5 per 10,000 population) subsequently developed neurotrophic keratitis.
  • According to the National Institute for Health Research, in 2014–2015, there were 2,426 hospital admissions for keratitis in England, equating to 10,437 bed days and 2,569 finished consultant episodes
  • Neurotrophic keratitis is considered a rare disease; however, the prevalence of keratitis is gradually rising, which in turn increases the number of cases of neurotrophic keratitis. These factors boost the growth of the global neurotrophic keratitis market.

Surge in Investments in Research and Clinical Study, and Product Approvals and Launches to Augment Global Market

  • In May 2019, RegeneRx Biopharmaceuticals, Inc. was granted a new U.S. patent for a method of preventing or treating dry eye syndrome by administering Tβ4 with non-active ingredients to provide improved pharmacodynamics
  • In August 2018, Dompé announced that the U.S. Food and Drug Administration (FDA) had approved cenegermin (Oxervate), a breakthrough therapy for neurotrophic keratitis (NK), a rare and progressive eye disease that can lead to corneal scarring and vision loss
  • In June 2017, Recordati signed an exclusive license agreement on a global basis with MimeTech, an Italy-based development stage company for the development and subsequent commercialization of a low molecular weight peptidomimetic of human nerve growth factor (NGF) for the treatment of neurotrophic keratitis
  • Hence, increase in interest and rise in growth strategies of key players are the factors fueling the growth of the global neurotrophic keratitis market

High Cost of Treatment to Hamper Neurotrophic Keratitis Market

  • According to data published in 2017 by the Royal College of Ophthalmologists (RCOphth), serum eye drops is a highly specialized and high cost intervention for patients with ocular surface disease
  • A study published in 2018 by SAGE Journals titled, “Epidemiology and economic impact of moderate and severe neurotrophic keratopathy in Italy”, indicated that the mean per patient annual cost of neurotrophic keratitis in the healthcare setting in Italy is substantial and doubles with disease severity
  • Out-of-pocket expenses associated with chronic use of topical eye gels and drops (e.g. RGTA Technology–based solutions) and challenges with autologous serum drops production affect the treatment approach and sequence as well as access to treatment of neurotrophic keratitis
  • The factors mentioned above are anticipated to restrain the global neurotrophic keratitis market

North America to Account for Major Share of Neurotrophic Keratitis Market

  • North America is projected to account for leading share of the global neurotrophic keratitis market due to rise in product approvals, well-established health care infrastructure, increase in technological advancements, rise in number of well-equipped laboratories, surge in research & developmental activities in neurotrophic keratitis, growing healthcare industry, and presence of key players
  • The neurotrophic keratitis market in Asia Pacific is projected to grow at a rapid pace during the forecast period due to increase in geriatric population, rise in research & developmental activities, surge in initiatives by governments in the healthcare sector, and rise in interest of key players in expanding presence in the region

Neurotrophic Keratitis Market: Competition Landscape

  • This report profiles major players in the global neurotrophic keratitis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Key players operating in the global neurotrophic keratitis market include
    • Dompe farmaceutici S.p.A.,
    • Allergan,
    • ReGenTree, LLC, Alcon,
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.),
    • CONTACARE,
    • OHTO Pharmaceutical Co., Ltd.,
    • Pfizer, Inc.,
    • Neuroptika
    • Santen Pharmaceutical Co., Ltd.,
    • Johnson & Johnson,
    • Grand Pharma (China) Co., Ltd., and
    • Zhejiang CONBA Pharmaceutical Co., Ltd.

Neurotrophic Keratitis Market: Key Developments

  • Key players in the global neurotrophic keratitis market have adopted strategies such as regulatory approvals, advanced product development, launch of new products, increase in investments and funds, and acquisition & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the global neurotrophic keratitis market. A few strategies adopted by players operating in the global neurotrophic keratitis market are:
    • In March 2019, Dompé announced that the National Organization for Rare Disorders (NORD) had awarded it the 2019 Industry Innovation Award for Oxervate, a breakthrough therapy for neurotrophic keratitis (NK), which is a rare and progressive eye disease that can lead to corneal scarring and vision loss
    • In May 2017, Santen Pharmaceutical Co., Ltd. and Singapore Eye Research Institute announced a strategic, five-year extended collaboration designed to develop new technologies for unmet medical needs in key ophthalmology domain
    • In August 2016, Allergan plc entered into an agreement to acquire ForSight VISION5, a privately held, clinical-stage biotechnology company focused on eye care, for US$ 95.0 Mn upfront payment
  • The report on the global neurotrophic keratitis market discusses individual strategies followed by company profiles of manufacturers of neurotrophic keratitis treatment products. The competition landscape section has been included in the neurotrophic keratitis market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global neurotrophic keratitis market.

Neurotrophic Keratitis Market - Segmentation

Treatment Type

  • Drugs
    • Artificial Tears
    • Recombinant Human Nerve Growth Factors Eye Drops
    • Antibiotics
    • Bandage Contact Lens
    • Others
  • Surgical Intervention
    • Tarsorrhaphy
    • Amniotic Membrane Transplantation
    • Others

Application

  • Stage I
  • Stage II
  • Stage III

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Neurotrophic Keratitis Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of neurotrophic keratitis market?

The global neurotrophic keratitis market was worth US$ 91.6 Mn and is projected to reach a value of US$ 324 Mn by the end of 2027

What is the anticipated CAGR of the neurotrophic keratitis market in the forecast period?

Neurotrophic keratitis market is anticipated to grow at a CAGR of 17% during the forecast period

Which region is expected to project the highest market share in the global neurotrophic keratitis market?

North America accounted for a major share of the global neurotrophic keratitis market

What are the key driving factors for the growth of the neurotrophic keratitis market?

Neurotrophic keratitis market is driven by rise in reported cases of keratitis, increase in research & developmental activities, surge in awareness, and rise in co-morbidities & risk factors boost the growth of the market

Who are the key players in the global neurotrophic keratitis market?

Key players in the global neurotrophic keratitis market include Dompe farmaceutici S.p.A., Allergan, ReGenTree, LLC, Alcon, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), CONTACARE, OHTO Pharmaceutical Co., Ltd., Pfizer, Inc., Neuroptika, Santen Pharmaceutical Co., Ltd., Johnson & Johnson, Grand Pharma (China) Co., Ltd., and Zhejiang CONBA Pharmaceutical Co., Ltd.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neurotrophic Keratitis Market

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Neurotrophic Keratitis Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Disease Prevalence & Incidence Rate globally with key countries / Region

    5.2. Pipeline Analysis

    5.3. Key Industry Developments

6. Global Neurotrophic Keratitis Market Analysis and Forecast, by Treatment Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment Type, 2017–2027

        6.3.1. Drugs

            6.3.1.1. Artificial Tears

            6.3.1.2. Recombinant Human Nerve Growth Factors Eye Drop

            6.3.1.3. Oral Antibiotics

            6.3.1.4. Bandage Contact Lens

            6.3.1.5. Others

        6.3.2. Surgical Intervention

            6.3.2.1. Tarsorrhaphy

            6.3.2.2. Amniotic Membrane Transplantation

            6.3.2.3. Others

    6.4. Market Attractiveness, by Treatment Type 

7. Global Neurotrophic Keratitis Market Analysis and Forecast, by Stage 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Stage, 2017–2027

        7.3.1. Stage I

        7.3.2. Stage II

        7.3.3. Stage III

    7.4. Market Attractiveness Analysis, by Stage 

8. Global Neurotrophic Keratitis Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness Analysis, by Country/Region

9. North America Neurotrophic Keratitis Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast By Treatment Type, 2017–2027

        9.2.1. Drugs

            9.2.1.1. Artificial Tears

            9.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

            9.2.1.3. Oral Antibiotics

            9.2.1.4. Bandage Contact Lens

            9.2.1.5. Others

        9.2.2. Surgical Intervention

            9.2.2.1. Tarsorrhaphy

            9.2.2.2. Amniotic Membrane Transplantation

            9.2.2.3. Others

    9.3. Market Value Forecast, by Stage, 2017–2027

        9.3.1. Stage I

        9.3.2. Stage II

        9.3.3. Stage III

    9.4. Market Value Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis 

        9.5.1. By Treatment Type 

        9.5.2. By Stage 

        9.5.3. By Country

10. Europe Neurotrophic Keratitis Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment Type, 2017–2027

        10.2.1. Drugs

            10.2.1.1. Artificial Tears

            10.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

            10.2.1.3. Oral Antibiotics

            10.2.1.4. Bandage Contact Lens

            10.2.1.5. Others

        10.2.2. Surgical Intervention

            10.2.2.1. Tarsorrhaphy

            10.2.2.2. Amniotic Membrane Transplantation

            10.2.2.3. Others

    10.3. Market Value Forecast, by Stage, 2017–2027

        10.3.1. Stage I

        10.3.2. Stage II

        10.3.3. Stage III

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis 

        10.5.1. By Treatment Type 

        10.5.2. By Stage 

        10.5.3. By Country/Sub-region

11. Asia Pacific Neurotrophic Keratitis Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment Type, 2017–2027

        11.2.1. Drugs

            11.2.1.1. Artificial Tears

            11.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

            11.2.1.3. Oral Antibiotics

            11.2.1.4. Bandage Contact Lens

            11.2.1.5. Others

        11.2.2. Surgical Intervention

            11.2.2.1. Tarsorrhaphy

            11.2.2.2. Amniotic Membrane Transplantation

            11.2.2.3. Others

    11.3. Market Value Forecast, by Stage, 2017–2027

        11.3.1. Stage I

        11.3.2. Stage II

        11.3.3. Stage III

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis 

        11.5.1. By Treatment Type 

        11.5.2. By Stage 

        11.5.3. By Country/Sub-region

12. Latin America Neurotrophic Keratitis Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment Type, 2017–2027

        12.2.1. Drugs

            12.2.1.1. Artificial Tears

            12.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

            12.2.1.3. Oral Antibiotics

            12.2.1.4. Bandage Contact Lens

            12.2.1.5. Others

        12.2.2. Surgical Intervention

            12.2.2.1. Tarsorrhaphy

            12.2.2.2. Amniotic Membrane Transplantation

            12.2.2.3. Others

    12.3. Market Value Forecast, by Stage, 2017–2027

        12.3.1. Stage I

        12.3.2. Stage II

        12.3.3. Stage III

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis 

        12.5.1. By Treatment Type 

        12.5.2. By Stage 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Neurotrophic Keratitis Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment Type, 2017–2027

        13.2.1. Drugs

            13.2.1.1. Artificial Tears

            13.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop

            13.2.1.3. Oral Antibiotics

            13.2.1.4. Bandage Contact Lens

            13.2.1.5. Others

        13.2.2. Surgical Intervention

            13.2.2.1. Tarsorrhaphy

            13.2.2.2. Amniotic Membrane Transplantation

            13.2.2.3. Others

    13.3. Market Value Forecast, by Stage, 2017–2027

        13.3.1. Stage I

        13.3.2. Stage II

        13.3.3. Stage III

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis 

        13.5.1. By Treatment Type 

        13.5.2. By Stage 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (By Tier and Size of companies)

    14.2. Market Share/Position Analysis, by Company, 2018

    14.3. Company Profiles

        14.3.1. Dompe farmaceutici S.p.A.

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Growth Strategies

            14.3.1.3. SWOT Analysis

        14.3.2. Allergan

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Growth Strategies

            14.3.2.3. SWOT Analysis

        14.3.3. ReGenTree, LLC

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Growth Strategies

            14.3.3.3. SWOT Analysis

        14.3.4. Alcon

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Growth Strategies

            14.3.4.3. SWOT Analysis

        14.3.5. Bausch & Lomb Incorporated (Bausch Health Companies Inc.) 

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Growth Strategies

            14.3.5.3. SWOT Analysis

        14.3.6. CONTACARE

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Growth Strategies

            14.3.6.3. SWOT Analysis

        14.3.7. ROHTO Pharmaceutical Co., Ltd. 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Growth Strategies

            14.3.7.3. SWOT Analysis

        14.3.8. Pfizer, Inc. 

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Growth Strategies

            14.3.8.3. SWOT Analysis

        14.3.9. Neuroptika 

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Growth Strategies

            14.3.9.3. SWOT Analysis

        14.3.10. Santen Pharmaceutical Co., Ltd.

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Growth Strategies

            14.3.10.3. SWOT Analysis

        14.3.11. Johnson & Johnson

            14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.11.2. Growth Strategies

            14.3.11.3. SWOT Analysis

        14.3.12. Grand Pharma (China) Co., Ltd.

            14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.12.2. Growth Strategies

            14.3.12.3. SWOT Analysis

        14.3.13. Zhejiang CONBA Pharmaceutical Co., Ltd.

            14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.13.2. Growth Strategies

            14.3.13.3. SWOT Analysis

List of Tables

Table 01: Neurotrophic Keratitis Pipeline Analysis - Phase III and Phase II

Table 02: Neurotrophic Keratitis Pipeline Analysis - Phase I

Table 03: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 04: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 06: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 07: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Region, 2017–2027

Table 08: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country, 2017–2027 

Table 09: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 10: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 11: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 12: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 13: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 14: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 15: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 16: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 17: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 18: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 19: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 20: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 21: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 22: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 23: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 24: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 25: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 26: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 27: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

Table 28: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027 

Table 29: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027

Table 30: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017–2027

Table 31: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017–2027

Table 32: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017–2027

List of Figures

Figure 01: Global Neurotrophic Keratitis Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027

Figure 02: Global Neurotrophic Keratitis Market Value (US$ Mn), by Treatment Type, 2018 (A)

Figure 03: Global Neurotrophic Keratitis Market, Top 3 Trends, 2018

Figure 04: Market Overview

Figure 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, 2017–2027

Figure 06: Global Neurotrophic Keratitis Market Value Share, by Treatment Type, 2018

Figure 07: Global Neurotrophic Keratitis Market Value Share, by Stage, 2018

Figure 08: Global Neurotrophic Keratitis Market Value Share, by Region, 2018

Figure 09: Global Neurotrophic Keratitis Market Value Share, by Drugs, 2018

Figure 10: Global Neurotrophic Keratitis Market Value Share, by Surgical Intervention, 2018

Figure 11: Global Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 12: Global Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 13: Global Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 14: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Drugs, 2017–2027

Figure 15: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Surgical Intervention, 2017–2027

Figure 16: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 17: Global Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 18: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage I, 2017–2027

Figure 19: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage II, 2017–2027

Figure 20: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage III, 2017–2027

Figure 21: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 22: Global Neurotrophic Keratitis Market Value Share Analysis, by Region, 2018 and 2027

Figure 23: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Region, 2019–2027

Figure 24: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 25: North America Neurotrophic Keratitis Market Value Share Analysis, by Country, 2018 and 2027

Figure 26: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Country, 2019–2027

Figure 27: North America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 28: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 29: North America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 30: North America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 31: North America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 32: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 33: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 34: Europe Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 35: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 36: Europe Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 37: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 38: Europe Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 39: Europe Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 40: Europe Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 41: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 42: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 43: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 44: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 45: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 46: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 47: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 48: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 49: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 50: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 51: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 52: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 53: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 54: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 55: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 56: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 57: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 58: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 59: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 60: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027

Figure 61: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

Figure 62: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019–2027

Figure 63: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027

Figure 64: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019–2027

Figure 65: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027

Figure 66: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027

Figure 67: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027

Figure 68: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019–2027

Figure 69: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

691

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved